<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856869</url>
  </required_header>
  <id_info>
    <org_study_id>NRL972-02/2003(ACPS)</org_study_id>
    <nct_id>NCT00856869</nct_id>
  </id_info>
  <brief_title>Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers</brief_title>
  <official_title>A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was conducted to describe and compare the plasma pharmacokinetics of NRL972&#xD;
      administered after a standard meal and while fasted in patients with hepatic cirrhosis&#xD;
      (Child-Turcotte-Pugh [CTP] class A-C), NASH, young and elderly healthy males, and young and&#xD;
      elderly healthy females, to assess the effects of liver dysfunction, gender, age and prandial&#xD;
      intestinal hyperaemia on the clearance of NRL972. In addition, the study was to provide&#xD;
      information on the safety and tolerability of repeated intravenous doses of NRL972 in these&#xD;
      populations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance of NRL972 after a standard meal and while fasted in healthy volunteers, patients with NASH and patients with hepatic cirrhosis.</measure>
    <time_frame>Up to 4 hours post administration of NRL972</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events and changes in physical findings from baseline</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of vital signs: blood pressure, pulse rate</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on electrocardiogram</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in haematology, clinical chemistry, urinalysis</measure>
    <time_frame>Up to 4 hours post-dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hepatic Cirrhosis</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>1 YM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 EM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly males</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 YF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy young females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 EF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly females</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 NASH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with presumed NASH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 CTP-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hepatic cirrhosis CTP-class A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 CTP-BC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hepatic cirrhosis CTP-class B and C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>1 YM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>2 EM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>3 YF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>4 EF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>5 NASH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>6 CTP-A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRL972</intervention_name>
    <description>Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal</description>
    <arm_group_label>7 CTP-BC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General - all subjects&#xD;
&#xD;
          1. Males or females (females of non-childbearing potential or of childbearing potential&#xD;
             while taking medically appropriate contraception)&#xD;
&#xD;
          2. Caucasian&#xD;
&#xD;
          3. BMI: between 19 and 34 kg.m-2&#xD;
&#xD;
          4. BW: between 45 and 110 kg&#xD;
&#xD;
          5. willing and able to provide informed consent Healthy volunteers (group N)&#xD;
&#xD;
          6. Age: 18 - 40 years (inclusive) e.g. &gt; 60 years&#xD;
&#xD;
          7. Assessed as healthy based on the pre study examination Hepatic cirrhosis&#xD;
&#xD;
          8. Age: 18 - 75 years&#xD;
&#xD;
          9. stable compensated liver cirrhosis (cryptogenic, posthepatic, alcoholic) with&#xD;
             histo-logical or macroscopic (e.g. laparascopy, biopsy, ultrasound sonography or other&#xD;
             adequate imaging techniques) confirmation Nonalcoholic steatohepatitis (NASH)&#xD;
&#xD;
         10. Age: 18 - 75 years&#xD;
&#xD;
         11. Diagnosis of NASH confirmed by liver biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General - all subjects&#xD;
&#xD;
          1. Previous participation in the trial&#xD;
&#xD;
          2. Participant in any other trial during the last 90 days&#xD;
&#xD;
          3. Donation of blood during the last 60 days or a history of blood loss exceeding 450 mL&#xD;
             within the last 3 months&#xD;
&#xD;
          4. History of any clinically relevant allergy&#xD;
&#xD;
          5. Uncontrolled diabetes mellitus or any further intolerability of the Galactose test&#xD;
&#xD;
          6. Presence of acute or chronic infection&#xD;
&#xD;
          7. Resting systolic blood pressure &gt; 160 or &lt; 90 mmHg, diastolic blood pressure &gt; 95 or &lt;&#xD;
             50 mmHg&#xD;
&#xD;
          8. Clinically relevant ECG-abnormalities, prolonged QTc with &gt; 450 msec in males and &gt;&#xD;
             460 msec in females in particular&#xD;
&#xD;
          9. Clinically relevant ECG-abnormalities that constitute a contraindication for the&#xD;
             Lido-cain-MEG'-X-test&#xD;
&#xD;
         10. Positive HIV test&#xD;
&#xD;
         11. Positive alcohol or urine drug test on recruitment&#xD;
&#xD;
         12. Daily use of &gt; 30 gr alcohol&#xD;
&#xD;
         13. Smoking more than 15 cigarettes/day or equivalent of other tobacco products&#xD;
&#xD;
         14. Use of prohibited medication&#xD;
&#xD;
         15. Suspicion or evidence that the subject is not trustworthy and reliable&#xD;
&#xD;
         16. Suspicion or evidence that the subject is not able to make a free consent or to&#xD;
             under-stand the information in this regard&#xD;
&#xD;
             General - all females&#xD;
&#xD;
         17. Positive pregnancy test&#xD;
&#xD;
         18. Lactating&#xD;
&#xD;
         19. Not using appropriate contraception in premenopausal women All healthy subjects&#xD;
&#xD;
         20. Presence or history of any relevant comorbidity (list of past and present diseases&#xD;
             will be reviewed by an expert panel)&#xD;
&#xD;
         21. Presence of any relevant abnormality in the laboratory safety tests, especially low&#xD;
             haemoglobin, increased liver enzymes, reduced serum creatinine (laboratory test&#xD;
             abnormalities will be reviewed by an expert panel)&#xD;
&#xD;
         22. Positive serology for HBsAg, anti HBc and anti HCV&#xD;
&#xD;
         23. History of alcohol and/or drug abuse.&#xD;
&#xD;
             Patients with hepatic disease&#xD;
&#xD;
         24. Biliary liver cirrhosis&#xD;
&#xD;
         25. Liver impairment due to space-occupying processes (e.g. carcinoma)&#xD;
&#xD;
         26. State after liver transplantation or patient scheduled for liver transplantation&#xD;
&#xD;
         27. Fluctuating or rapidly deteriorating hepatic function&#xD;
&#xD;
         28. Significant bleeding diathesis&#xD;
&#xD;
         29. Oesophageal bleeding within the last 8 weeks before study entry&#xD;
&#xD;
         30. Ascites &gt; 6 L on abdominal US&#xD;
&#xD;
         31. Number Connection test: time to connect 25 consecutive numbers &gt; 30 sec&#xD;
&#xD;
         32. Presence or history of any relevant comorbidity other than hepatic disease (list of&#xD;
             past and present diseases will be reviewed by an expert panel)&#xD;
&#xD;
         33. Clinically relevant abnormal laboratory values other than those associated or&#xD;
             sufficiently explained by the existing liver disease (laboratory test abnormalities&#xD;
             will be reviewed by an expert panel)&#xD;
&#xD;
         34. History of drug or alcohol abuse within 2 months prior to dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zahariy Krastev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Ivan Rilski's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans-Jürgen Gruss, MD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMHAPT St. Ivan Rilski's University Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>March 5, 2009</last_update_submitted>
  <last_update_submitted_qc>March 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President Clinical Development</name_title>
    <organization>Norgine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

